498 related articles for article (PubMed ID: 34067020)
21. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Tang ZY; Wu YL; Gao SL; Shen HW
J Surg Res; 2008 Mar; 145(1):111-23. PubMed ID: 17714734
[TBL] [Abstract][Full Text] [Related]
22. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
23. Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition.
Li X; Roife D; Kang Y; Dai B; Pratt M; Fleming JB
Oncogene; 2016 Sep; 35(37):4881-90. PubMed ID: 26876211
[TBL] [Abstract][Full Text] [Related]
24. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Kunnumakkara AB; Guha S; Krishnan S; Diagaradjane P; Gelovani J; Aggarwal BB
Cancer Res; 2007 Apr; 67(8):3853-61. PubMed ID: 17440100
[TBL] [Abstract][Full Text] [Related]
25. P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.
Jagadeeshan S; Subramanian A; Tentu S; Beesetti S; Singhal M; Raghavan S; Surabhi RP; Mavuluri J; Bhoopalan H; Biswal J; Pitani RS; Chidambaram S; Sundaram S; Malathi R; Jeyaraman J; Nair AS; Venkatraman G; Rayala SK
Ann Oncol; 2016 Aug; 27(8):1546-56. PubMed ID: 27117533
[TBL] [Abstract][Full Text] [Related]
26. An increased expression of long non-coding RNA PANDAR promotes cell proliferation and inhibits cell apoptosis in pancreatic ductal adenocarcinoma.
Jiang Y; Feng E; Sun L; Jin W; You Y; Yao Y; Xu Y
Biomed Pharmacother; 2017 Nov; 95():685-691. PubMed ID: 28886528
[TBL] [Abstract][Full Text] [Related]
27. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
28. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
[TBL] [Abstract][Full Text] [Related]
30. Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
Fu D; Yan J; Zhang Z; Liu Y; Ma X; Ding J; Yang S; Zhao R; Chang A; Gao C; Liu J; Zhao T; Wang X; Huang C; Gao S; Ma Y; Tang B; Feng Y; Wang H; Hao J
Cancer Biol Med; 2023 Jun; 20(8):599-626. PubMed ID: 37381714
[TBL] [Abstract][Full Text] [Related]
31. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation.
Ju HQ; Gocho T; Aguilar M; Wu M; Zhuang ZN; Fu J; Yanaga K; Huang P; Chiao PJ
Mol Cancer Ther; 2015 Mar; 14(3):788-98. PubMed ID: 25527634
[TBL] [Abstract][Full Text] [Related]
33. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
34. SERP1 is a novel marker of poor prognosis in pancreatic ductal adenocarcinoma patients via anti-apoptosis and regulating SRPRB/NF-κB axis.
Ma Q; Wu X; Wu J; Liang Z; Liu T
Int J Oncol; 2017 Oct; 51(4):1104-1114. PubMed ID: 28902358
[TBL] [Abstract][Full Text] [Related]
35. Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells.
Arora S; Bhardwaj A; Srivastava SK; Singh S; McClellan S; Wang B; Singh AP
PLoS One; 2011; 6(6):e21573. PubMed ID: 21720559
[TBL] [Abstract][Full Text] [Related]
36. Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
Ding L; Madamsetty VS; Kiers S; Alekhina O; Ugolkov A; Dube J; Zhang Y; Zhang JS; Wang E; Dutta SK; Schmitt DM; Giles FJ; Kozikowski AP; Mazar AP; Mukhopadhyay D; Billadeau DD
Clin Cancer Res; 2019 Nov; 25(21):6452-6462. PubMed ID: 31533931
[TBL] [Abstract][Full Text] [Related]
37. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
[TBL] [Abstract][Full Text] [Related]
38. Metallothionein-1G suppresses pancreatic cancer cell stemness by limiting activin A secretion
Li K; Zhang Z; Mei Y; Yang Q; Qiao S; Ni C; Yao Y; Li X; Li M; Wei D; Fu W; Guo X; Huang X; Yang H
Theranostics; 2021; 11(7):3196-3212. PubMed ID: 33537082
[TBL] [Abstract][Full Text] [Related]
39. Requirement of nuclear factor κB for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis.
Stadel D; Cristofanon S; Abhari BA; Deshayes K; Zobel K; Vucic D; Debatin KM; Fulda S
Neoplasia; 2011 Dec; 13(12):1162-70. PubMed ID: 22241962
[TBL] [Abstract][Full Text] [Related]
40. A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
Yang S; He P; Wang J; Schetter A; Tang W; Funamizu N; Yanaga K; Uwagawa T; Satoskar AR; Gaedcke J; Bernhardt M; Ghadimi BM; Gaida MM; Bergmann F; Werner J; Ried T; Hanna N; Alexander HR; Hussain SP
Cancer Res; 2016 Jul; 76(13):3838-50. PubMed ID: 27197190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]